Cipla Limited (CIPLA) — Board Meeting Announcement

· NSE 🟡 Notable Neutral
📢 Key Event
Board approved 90th AGM on 25 June 2026, ESOP/ESAR grants, cost auditor appointment, and Kulkarni's promotion.
🔄 What Changed
90th AGM scheduled for 25 June 2026; ESOP/ESAR grants details disclosed; M/s Joshi Apte appointed cost auditors for FY 2026-27; Sushrut Kulkarni appointed President & Global Chief – Integrated Product Development effective 18 May 2026.
🔮 What's Next
90th AGM scheduled for 25 June 2026.
💡 Investor Takeaway
The board set a 25 June 2026 date for the annual meeting, finalized employee equity grants, and added a new executive to drive product development.

Cipla's board approved convening its 90th Annual General Meeting on 25 June 2026, granted stock options and ESARs under the 2013-A and 2021 schemes, appointed M/s Joshi Apte & Associates as cost auditors for FY 2026-27, and named Sushrut Kulkarni as President & Global Chief – Integrated Product Development effective 18 May 2026.

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.